# Moderna's mRNA-based seasonal flu vaccine demonstrated superior efficacy compared to conventional flu shots.

*biotech · news · 2026-05-06 · Devdiscourse*

## Key points

- Moderna's mRNA flu vaccine showed 26.6% higher effectiveness than GSK's standard-dose flu shot.
- Over 40,000 adults aged 50 and older participated in the late-stage global trial.
- FDA initially rejected Moderna's vaccine due to concerns over how the vaccine's performance was compared.
- If approved, Moderna's would be the first U.S. seasonal flu vaccine using mRNA technology.
- Ongoing regulatory reviews in the EU, Canada, and Australia could influence upcoming approvals.

**Companies:** Moderna
**Countries:** United States, Canada, Australia, European Union

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3899328-modernas-flu-revolution-mrna-vaccine-outperforms-conventional-shots)

---

Canonical: https://newsio.io/n/0d6d92f4-4e18-4028-85ae-f8907fb6e6bd/modernas-mrna-based-seasonal-flu-vaccine-demonstrated-superior-efficacy-compared
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works